Table 2.

Demography and Tumor Characteristics of the Radical Prostatectomy (RP) Population in the Bicalutamide EPC Program²¹

	% Patients*
	Bicalutamide
	150 mg/d + RP	Placebo + RP
	(n = 2236)	(n = 2218)
Mean age (range), y	63.6 (42–89)	66.9 (38–93)
Disease stage (pathological)
T1/T2	61	62
T3	37	37
T4	2	1
Nodal status
N0	90	89
Nx	9	10
N+	2	2
Gleason score (tumor grade)
7–10 (Poorly differentiated)	45	43
5–6 (Moderately differentiated)	45	46
2–4 (Well differentiated)	10	11
Trial
23	59	60
24	37	37
25	4	4

^*Unless otherwise stated.